Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures

Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures

Abstract Background Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare hereditary kidney cancer syndrome in which affected individuals are at risk of skin and uterine leiomyomatosis and kidney cancer. HLRCC-associated kidney cancer is a lethal disease with a highly aggressive behav...

Full description

Bibliographic Details
Main Authors: Inkeun Park, Young Sup Shim, Heounjeong Go, Bum Sik Hong, Jae Lyun Lee
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Urology
Subjects:
Hereditary leiomyomatosis and renal cell carcinoma
Metastasis
Bevacizumab
Erlotinib
Online Access:http://link.springer.com/article/10.1186/s12894-019-0484-2

Internet

http://link.springer.com/article/10.1186/s12894-019-0484-2

Similar Items